Roche Holding AG (RHHBY)
OTCMKTS
· Delayed Price · Currency is USD
55.39
+1.20 (2.21%)
At close: Mar 6, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
350.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
| Tian'an Technology Group | 8 |
| Vaxart | 105 |
Roche Holding AG News
- 16 hours ago - 2 Underrated Weight Loss Stocks to Buy Now - The Motley Fool
- 1 day ago - Roche (RHHBY) Diagnostics Division Faces Tariff Challenges - GuruFocus
- 1 day ago - Roche chairman still expects diagnostics hit from US tariffs - Reuters
- 2 days ago - Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics' - CNBC
- 2 days ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - GlobeNewsWire
- 2 days ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Business Wire
- 2 days ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - Benzinga
- 2 days ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Benzinga